toolong. Good analogy, roulette wheel. It apparently remains too close to call re. the "ifs,whethers,&whats" of Bavi (and Cotara). These initial human trials with naked Bavi will bolster safety profile for anti-PS, a critical long-range trove of information, but it might be a close call re. important survival numbers with Bavi. A close call with the FDA, but probably a favorable outcome there as well. But we know naked Bavi is no barnburner when used an an immunological booster only instead of as an "armed" MAB, packing a payload of cancercidal small particles in one arm while grabbing onto cancer/viral cell-membrane -PS with the other. One solace is PPHM's strong relationship with Affitec which is brewing a much better (humanized? armable?) Bavi, and apparently has immediate clinical trials outlets in Russia.
Anti-TNT therapy (Cotara)has definitely turned a few heads, being able to deliver a punch when injected inside tumor. But like humanizing MAB Bavi, pursuit of a smaller/humanized Cotara is the goal, and that work is proceeding apace. I plan to buy some more shares of PPHM next week (early). All imo.
News 
Market Data 
Discover 
